Timberlyne Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company focused on the development of new therapies for autoimmune disorders, raised $180M in Series A funding.
The round was led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP, and 3H Health Investment.
The company intends to use the funds to expand operations and its R&D sector.
Formed by Mountainfield Venture Partners, a biopharma company creation firm, in partnership with Keymed Biosciences Inc. (HKEX: 02162), Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for unmet medical needs. Its lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38.
By targeting CD38, which is highly expressed on plasma cells, NK cells, and other immune cells, CM313 modulates multiple immune cell types leading to both rapid and durable responses across a range of autoimmune diseases and cancers.
Timberlyne has obtained exclusive development and commercialization rights to CM313 worldwide outside of greater China from Keymed Biosciences. Under the terms of the licensing agreement, Keymed will receive an undisclosed upfront payment, as well as future cash milestones, royalties on any potential future net sales, and equity ownership in Timberlyne. Keymed retains development and commercialization rights in greater China.
FinSMEs
10/01/2025